The Eye Drug That Just Can't Take a Hint

But there was a silver lining: reproxalap did show statistical significance on a secondary endpoint, the Schirmer's test, which measures tear production. So for the next trial, TRANQUILITY-2, Aldeyra essentially swapped the goalposts. TRANQUILITY-2 then met its target.

If that feels a little like a student who failed the math test asking to be graded on their essay instead, you're picking up what the FDA is putting down. Regulators noted that sign data (like redness and tear production) lacked a clear connection to actual symptom relief for patients. In other words: proving you can change a lab measurement doesn't prove patients feel better.

Another field trial failed its primary endpoint entirely. When you line up the wins and losses across all these studies, you get what the FDA diplomatically called "inconsistent" results. The positive findings look less like a signal and more like noise.

Wall Street's Patience Finally Ran Out

Investors had been nervously watching this saga unfold for years. The stock had already been drifting lower in March, falling from about $5.62 on March 2 to $4.23 by March 16, a roughly 25% decline that suggested the market was bracing for bad news.

Then the CRL dropped, and so did the floor. H.C. Wainwright, an investment bank that covers biotech, downgraded Aldeyra to Neutral with a $2 price target. For context, that's an 80% haircut from where Oppenheimer had the stock rated (Outperform at $10) back in April 2024. The mood swing from Wall Street tells you everything: the market has largely given up on reproxalap.

The AbbVie Wildcard

One detail makes this story even more interesting. AbbVie holds an option on reproxalap with a $100 million milestone payment tied to FDA approval. That's a significant chunk of change sitting on the table, but it only materializes if the drug actually gets across the finish line.

With three rejections in hand, that milestone is starting to look like a lottery ticket rather than a paycheck. Whether AbbVie maintains its interest or quietly walks away could shape Aldeyra's next chapter.

So What Happens Now?

The FDA, to its credit, didn't just slam the door shut. Regulators suggested that Aldeyra investigate why its trials keep failing and try to identify specific patient populations where reproxalap might show clearer benefits. Notably, the agency didn't request new trials or additional data, which is an unusual move. It's almost like the FDA is saying, "We're not going to tell you what to do next, because we're not sure there is a next."

Aldeyra isn't ready to walk away. The company plans to request a Type A meeting with the FDA (a fast-track discussion typically scheduled within 30 days) to clarify what, if anything, could lead to approval. CEO Todd Brady has emphasized the rapid symptom relief observed in some trial results as a potential path forward.

Financially, Aldeyra isn't in immediate danger. The company reported $70 million in cash as of December 31, 2025, enough to fund operations into 2028. R&D spending dropped 46.8% year-over-year to $25.7 million, which makes sense when your lead program keeps hitting a regulatory brick wall. The balance sheet is clean: total debt sits at just $15.25 million against shareholder equity of $44.25 million.

But cash without a viable product is just a slow countdown. Without reproxalap, Aldeyra's pipeline options are limited, and every month that passes without a clear regulatory path burns through that runway.

A Cautionary Tale for Ophthalmic Drug Development

Aldeyra's story highlights a broader challenge in eye disease drug development. The FDA has high standards for efficacy, and "close enough" doesn't cut it. Changing your primary endpoint after a trial fails, then pointing to inconsistent wins across multiple studies, is a strategy that regulators see right through.

For the dry eye market (which is massive and growing), the lesson is clear: you need clean, reproducible data showing patients actually feel better. Lab measurements and statistical gymnastics won't get you there.

Three rejections is rare in biotech. Most companies pivot or cut their losses after two. Aldeyra's willingness to keep fighting shows either admirable persistence or an inability to read the room. The next 30 days, and whatever the FDA says in that Type A meeting, will likely determine which one it is.

Bicycle Therapeutics Just Torched Its Best Shot at a Blockbuster

Bicycle Therapeutics gutted its lead cancer drug, cut 30% of staff, and is betting what's left on a backup candidate with its own baggage. The company that pioneered bicycle toxin conjugates just learned that inventing a category doesn't guarantee you'll win in it.